ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic

By sjmartinez • October 31, 2024

Keshtkar-Jahromi M, Anstrom KJ, Barkauskas C, Brown SM, Daar ES, Fischer W, Gibbs KW, Higgs ES, Hughes MD, Jagannathan P, LaVange L, Lindsell CJ, Nayak SU, Paredes R, Parmar M, Peltan ID, Proschan M, Shotwell MS, Vock DM, Yokum T, Adam SJ. ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic. J Clin Transl Sci. 2024 Oct 15;8(1):e151. doi: 10.1017/cts.2024.1. PMID: 39478775; PMCID: PMC11523015.

Tags: ACTIV, Clinical Trial, covid-19, design, Infectious Diseases, lessons, Publications

The hantavirus question we are not asking

Hensley LE, Halbrook M, Hoff NA, Merritt S, Olinger GG, Skinner B, von Fricken ME, Kindrachuk J, Rimoin AW. The hantavirus question we are not[...]

Advanced HIV Disease at First Diagnosis in South Brazil Extended Beyond Traditionally Targeted Populations: A 10-Year Hospital-Based Study (2015-2024)

Hernandez CJ, Fonseca PM, Noal A, Zywica M, Cambou MC, Varella IRDS, Santos BR, de Melo MG, Nielsen-Saines K. Advanced HIV Disease at First Diagnosis[...]

Does AI know how to choose wisely? Do not trust and definitely verify when using generative AI in stewardship operations

Dora AV, Benjamin LN, Graber CJ, Branch-Elliman W. Does AI know how to choose wisely? Do not trust and definitely verify when using generative AI[...]